Compare RNA & MCGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | MCGA |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 241.0M |
| IPO Year | 2025 | 2025 |
| Metric | RNA | MCGA |
|---|---|---|
| Price | $14.01 | $10.32 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $69.26 | N/A |
| AVG Volume (30 Days) | ★ 127.7K | 83.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.13 | $10.09 |
| 52 Week High | $73.06 | $10.83 |
| Indicator | RNA | MCGA |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 75.28 |
| Support Level | $12.72 | $10.10 |
| Resistance Level | $14.05 | N/A |
| Average True Range (ATR) | 0.51 | 0.02 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 94.17 | 90.00 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Yorkville Acquisition Corp is a blank check company.